Alkermes Stock News

ALKS earnings call for the period ending December 31, 2021.

Alkermes plc''s (NASDAQ: ALKS ) Q4 sales increased 16% Y/Y to $324.5 million , beating the consensus of $308.69 million. Net sales of proprietary products were $178.9 million, compared to $148.96 million in the prior year. Net sales of Vivitrol were $92.04 million, compared to $80.05 million in the prior year. Net sales of Aristada were $78.67 million, compared to $68.91 … Full story available on Benzinga.com

The biotech smashed analyst estimates in its final quarter of 2021.

Alkermes <> rose following its Q4 results, which beat analysts'' estimates.Q4 total revenues grew ~16% Y/Y $324.5M

Alkermes (ALKS) delivered earnings and revenue surprises of 76.92% and 1.44%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Alkermes plc. (ALKS) CEO Richard Pops on Q4 2021 Results - Earnings Call Transcript

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Hookipa Gets $15M Upfront Payment And Equity Investment From Gilead Following Amended HIV Study Agreem

Alkermes (NASDAQ: ALKS ) reported its Q4 earnings results on Wednesday, February 16, 2022 at 07:00 AM. Here''s what investors need to know about the announcement. Also check this: Executives Buying These 5 Penny Stocks Earnings Alkermes beat estimated earnings by 109.09%, reporting an EPS of $0.23 versus an estimate of $0.11. Revenue was up $44.47 million from the same period … Full story available on Benzinga.com

Alkermes press release (ALKS): Q4 Non-GAAP EPS of $0.23 beats by $0.10.Revenue of $324.5M (+15.9% Y/Y) beats by $17.95M.Shares -0.51% PM.

DUBLIN, Feb. 16, 2022 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today reported financial results for the quarter and year ended Dec. 31, 2021 and provided financial expectations for 2022. "In 2021, we made significant progress against our strategic priorities of growing our commercial…

Alkermes (ALKS) delivered earnings and revenue surprises of 76.92% and 1.44%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Alkermes (NASDAQ:ALKS) is scheduled to announce Q4 earnings on Wednesday, Feb. 16, before market open.The consensus EPS estimate is $0.17 (+70% Y/Y)

Biotech stocks moved back and forth amid some volatility before finishing the week ending Feb. 11 modestly lower, reversing the gains from the previous week. Earnings news flow continued to dominate